The Drug Enforcement Administration announced Wednesday it’s making research into the non-intoxicating cannabis compound cannabidiol (CBD) easier, but advocates for legal access to what appears an effective treatment for epilepsy say the change doesn’t go nearly far enough.
Christmas came early for cannabis research scientists. The U.S. Drug Enforcement Agency (DEA) decided to ease some of the regulatory requirements that had been imposed on those who were conducting FDA-approved clinical trials on cannabidiol (CBD).
The Drug Enforcement Administration is not having a great year.
The chief of the agency stepped down in April under a cloud of scandal.
DEA chief Chuck Rosenberg on Wednesday rejected the notion that smoking marijuana is "medicine," calling the premise a "joke."
Steven Nelson ~ U.S. News & World Report ~
Authorities claim the plants were marijuana, not hemp – but evidence is lacking.
Copyright 2019 - 2024. WeedWorthy.com is a news division of MjLink.com, Inc.. All rights reserved. WeedWorthy
To contact the following departments, dial 1-844-420-4208 - Sales: Ext. #2 - Support: Ext. #3 - Investor Relations: Ext. #6
By using this website, you agree and understand that, by law: You MUST be at least 21 years of age to view any content on this website. To view the complete Terms of Use and Privacy Policy for this website, Click Here!
